PMID-34380875 – Pentadecapeptide BPC 157 and the Central Nervous System
Vukojevic J, Milavic M, Perovic D, Ilić S, Čilić AZ, Đuzel A, Sikiric P et al. "Pentadecapeptide BPC 157 and the central nervous system," Neural Regeneration Research, 2022;17(3):482-487. doi:10.4103/1673-5374.320969
Quick Reference
| Property | Value |
|---|---|
| PMID | 34380875 |
| DOI | 10.4103/1673-5374.320969 |
| Year | 2022 |
| Journal | Neural Regeneration Research |
| Study Type | Narrative Review |
| Evidence Level | V |
| Sample | Review of preclinical studies on BPC 157 and CNS |
| Peptide(s) Studied | BPC-157 |
Key Findings
- BPC 157 counteracts various CNS disturbances including stroke, traumatic brain injury (TBI), and spinal cord injury in animal models
- Ameliorates schizophrenia-like behavioral symptoms induced by dopaminergic perturbations
- Modulates the NO system as a key mechanism for CNS effects
- Counteracts both dopamine overactivity (amphetamine models) and dopamine deficiency (MPTP/6-OHDA models)
- Peripheral administration (SubQ, oral) produces central effects, suggesting blood-brain barrier penetration or indirect signaling
- All CNS disturbances studied "may be all resolved within the same agent's beneficial activity"
Study Design
Narrative review of preclinical evidence on BPC 157 in CNS injury and disease models. Covers stroke, TBI, spinal cord injury, and dopaminergic system perturbation models. Reviews both acute and chronic CNS injury paradigms.
Limitations
- Entirely preclinical (animal) evidence; no human neurological data exists
- All reviewed studies from the Sikiric research group (single-group concern)
- Mechanism of CNS access (BBB penetration vs. peripheral signaling) not definitively established
- Claims of broad-spectrum CNS efficacy may reflect publication bias from a single laboratory
Clinical Relevance
Provides the preclinical rationale for BPC 157 in neurological applications, particularly stroke recovery and neuroprotection. The dopaminergic modulation data is relevant for conditions like Parkinson's-like symptoms. However, the complete absence of human CNS data means all clinical applications are speculative. Relevant to the Cognitive Enhancement Protocol and Post-Stroke Recovery Protocol in the vault.
Related
#research #narrative-review #evidence-level-V